In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2

Kausar Begam Riaz Ahmed, Steven L. Warner, Andrew Chen, Eric S. Gourley, Xiaohui Liu, Hariprasad Vankayalapati, Roberto Nussenzveig, Josef T. Prchal, David J. Bearss, Charles J. Parker

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Objective: Constitutive activation of the Janus kinase 2 (JAK2) due to a somatic mutation (JAK2V617F) arising in hematopoietic stem cells plays a central role in the pathophysiology of myeloproliferative neoplasms (MPNs). To investigate the hypothesis that drugs that inhibit JAK2 have therapeutic potential, we developed a small molecule inhibitor, SGI-1252, that targets the adenosine triphosphate-binding and solvent pocket of the protein. Materials and Methods: Established cells lines each expressing different JAK2V617F copy numbers, a cell line transfected with wild-type and mutant JAK2, ex vivo expanded erythroid progenitor cells from patients with MPNs, and a murine xenograft model were used to characterize the activity of SGI-1252. Results: In vitro studies showed that SGI-1252 potently inhibits the kinase activity of wild-type JAK2, JAK2V617F and JAK1, but not JAK3. SGI-1252 blocked phosphorylation of signal transducers and activators of transcription 5, a downstream target of JAK2 and inhibited expression of the JAK2-dependent antiapoptotic gene BCL-XL. Additional studies confirmed induction of apoptosis in JAK2V617F-positive cell lines by SGI-1252. Moreover, cell lines transfected with either wild-type JAK2 or JAK2V617F were equally susceptible to the antiproliferative effects of SGI-1252 and the antiproliferative activity of SGI-1252 toward ex vivo-expanded erythroid progenitors from patients with polycythemia vera and primary myelofibrosis appeared independent of the JAK2V617F allele burden. Pharmacodynamic studies in a murine xenograft model demonstrated both anti-tumor activity and inhibition of signal transducers and activators of transcription 5 phosphorylation by SGI-1252, and the drug was active and well-tolerated whether delivered intraperitoneally or orally. Conclusions: Together, these studies support further development of SGI-1252 for clinical use.

Original languageEnglish (US)
Pages (from-to)14-25
Number of pages12
JournalExperimental hematology
Issue number1
StatePublished - Jan 2011
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research


Dive into the research topics of 'In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2'. Together they form a unique fingerprint.

Cite this